Pharmicell Co (A005690) Q3 2024 earnings summary

Executive summary

• Operates two main divisions: Bio-Medical (stem cell therapies, storage, cosmetics) and Bio-Chemical (nucleosides, PEG derivatives, flame retardants, electronic materials).

• Q3 2024 revenue was ₩43.4 billion, down from ₩56.2 billion in 2023 and ₩60.2 billion in 2022.

• Net income for Q3 2024 was ₩2.18 billion, a decrease from ₩3.58 billion in 2023 and ₩8.26 billion in 2022.

• Maintains strong R&D focus, with 13% of sales invested in research and several clinical trials ongoing.

Financial highlights

• Revenue for Q3 2024: ₩43.4 billion (down 22.8% YoY).

• Operating income: ₩1.51 billion (up from ₩1.30 billion in 2023, but down from ₩8.87 billion in 2022).

• Net income: ₩2.18 billion (down from ₩3.58 billion in 2023 and ₩8.26 billion in 2022).

• Cash and equivalents at Q3 2024: ₩10.1 billion, down from ₩13.7 billion at 2023 year-end.

• Total assets: ₩91.7 billion; total equity: ₩82.6 billion.

Outlook and guidance

• Continues to invest in R&D for new stem cell therapies and bio-chemical products.

• Expects ongoing demand for nucleosides and PEG derivatives due to global biotech and vaccine trends.

• Plans to expand production capacity for nucleosides and mPEG to meet anticipated demand.